News & Events

November 10, 2022

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce the Closing of their Previously Announced Business Combination

Approximately 80% of the shareholders of Vickers present at the meeting of Vickers shareholders in connection with the business combination voted in favor of the business combination.   Scliex’s shares of common stock and warrants are expected to begin trading on the Nasdaq Capital Market on November 11, 2022 under the ticker symbols “SCLX” and “SCLXW,” […] Read More »

November 10, 2022

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), Debuts on Nasdaq Under Ticker “SCLX”

Scilex Holding Company to Ring the Nasdaq Opening Bell on Friday November 11, 2022 at 9:30 a.m. ET Scilex plans to accelerate growth as a public company and advance further its non-opioid pain management therapeutic portfolio to transform the acute and chronic pain outpatient market Scilex will ring the Nasdaq opening bell at 9:30 a.m. […] Read More »

October 31, 2022

Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement on Form S-4, Date of Vickers Vantage Extraordinary General Meeting to Approve Proposed Business Combination

SEC declared Effectiveness of Vickers’s registration statement on Form S-4 Extraordinary General Meeting of Vickers Vantage Corp. I shareholders to approve the proposed Business Combination is scheduled to be held on November 9, 2022, at 10:00 a.m., Eastern Time Post-closing company will be renamed “Scilex Holding Company” upon closing of the Business Combination, with common […] Read More »

September 29, 2022

Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Pay Off of Remaining Balance of its Senior Secured Notes

Pre-emptive pay off of the Senior Secured Notes (the “Notes”) eliminated the prior $28.0 million increase in the principal amount of the Notes PALO ALTO and SAN DIEGO, CA. September 29, 2022 /Newswire/ — Scilex Holding Company (“Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment […] Read More »

August 30, 2022

Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation Of ZTlido®, For The Treatment Of Acute Low Back Pain (LBP)

SP-103 receives Fast Track Designation, which makes it eligible for some or all of the following: More frequent meetings or written communication with the FDA to discuss the SP-103 development plan and ensure collection of appropriate data needed to support drug approval Eligibility for Accelerated Approval or Priority Review, if relevant criteria are met Rolling […] Read More »

August 17, 2022

Scilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group LLC to Expand Commercialization of ZTlido® across certain designated territories including Middle East and North Africa

PALO ALTO, CA. August 17, 2022 /Newswire/ — Scilex Holding Company (“Scilex”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, today announced the signing of a Product Distribution Agreement (“Agreement”) for certain designated territories with CH Trading Group LLC (“CH Trading”), an international import, export […] Read More »

August 16, 2022

Scilex Holding Company, a Sorrento Company, Announces Expanding Coverage to 30 Million Lives And Will Continue To Work To Access An Additional 20 Million Lives With One Of The Largest National Pharmacy Benefit Managers (PBMs) For ZTlido® (lidocaine topical system) 1.8% 

30 million lives now covered by one of the largest national PBMs  Continue to work with this PBM to access an additional 20 million lives  The team continues to work with the national PBM’s and health plans to improve access further during 2022 with a goal to reach 250 million to 260 million lives in […] Read More »

July 7, 2022

Scilex Holding Company, a Sorrento Company, Has Entered A Term Sheet to Acquire Ancora Medical Inc.

Ancora Medical Inc. (“Ancora”) is a privately held medical technology company with an FDA approved product in February 2020, the Nerve Block Catheter Set which is indicated for surgical pain management during the pre-operative, perioperative and post-operative periods associated with general and orthopedic surgery. The device allows physicians to locate peripheral nerves by transferring electrical […] Read More »

July 5, 2022

Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors

PALO ALTO, CA. July 5, 2022 /Newswire/ — Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced today the appointment of the Honorable Tommy G. Thompson, […] Read More »

June 14, 2022

Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.

Gloperba is an FDA-approved, oral medication for treating painful gout flares in adults. Gout is a painful arthritic disorder affecting an estimated 8.7 million people in the United States1. As gout cases increase every year, treatment requirements increase. The gout treatment market is large and projected to be $8.3 billion in the US by 2025 […] Read More »

June 3, 2022

Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes

PALO ALTO and SAN DIEGO, CA. June 3, 2022 /Newswire/ — Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced that on June 3, 2022, it […] Read More »

June 2, 2022

Scilex Holding Company, a Sorrento Company, announces continued growth in ZTlido® in managed health care plans

Earlier this year, a national pharmacy benefit manager (PBM) moved a large percentage of its patients from not covered to covered, adding access to ZTlido for 5.5 million lives. ZTlido is now covered by managed health care plans representing approximately 190 million of the over 300 million covered lives across the United States1. PALO ALTO, […] Read More »

May 18, 2022

Scilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back Pain

Dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 in subjects with moderate to severe acute lower back pain.  The trial will enroll 80 patients with acute lower back pain. SP-103 is a pharmacologically validated drug candidate and has the […] Read More »

May 16, 2022

Scilex Holding Company, a Sorrento Company, and Vickers Vantage Corp. I announced today the filing of a Registration Statement on Form S-4 with the Securities and Exchange Commission relating to the previously announced proposed business combination between Scilex and Vickers

PALO ALTO, CA. and NEW YORK, NY. May 16, 2022 /Newswire/ –– Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”) and Vickers Vantage Corp. I (Nasdaq: VCKA “Vickers”) today announced the filing of a Registration Statement on Form S-4 (the “Registration Statement”) […] Read More »

May 11, 2022

Scilex, a Sorrento Company, Highlights Safety Data From Phase 1 Trial of SP-104, a Proprietary Low Dose Naltrexone for Fibromyalgia

SP-104 is a novel, proprietary, fixed dose, delayed burst release of low dose naltrexone hydrochloride, 4.5 mg, for treatment of fibromyalgia (FM). There is a clear medical need for new, safe and effective treatments with the potential to improve care for the estimated 10 million FM patients in the U.S. and more than 200 million […] Read More »

May 5, 2022

Scilex, a Sorrento Company, Announces Pivotal Phase 3 SP-102 (SEMDEXA™) Data Presentation At The American Society Of Interventional Pain (ASIPP) 2022 Annual Meeting

Results from a Pivotal Phase 3, DB, R, Placebo-controlled, Multicenter Trial of SP-102, a Novel Dexamethasone Injectable Formulation, for the Treatment of Patients with Lumbosacral Radiculopathy (Sciatica)  SP-102 (SEMDEXATM) is the first non-opioid novel injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular pain, and it contains no preservatives, surfactants, solvents, […] Read More »

April 28, 2022

Scilex Holding Company a majority-owned subsidiary of Sorrento Therapeutics, Inc., Appoints Highly Accomplished Life Science Executive, Elizabeth Czerepak, as Executive Vice President, Chief Financial Officer (CFO) and Chief Business Officer (CBO)

SAN DIEGO, CA AND PALO ALTO, CA. April 28, 2022 /Newswire/ — Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), who is a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced that Elizabeth Czerepak […] Read More »

April 27, 2022

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., to Present SP-102 (SEMDEXA™) Efficacy and Safety Data from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management at the 24th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP) in Las Vegas, NV.

PALO ALTO, CA. April 27, 2022 /Newswire/ — Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced that it will be presenting SP-102 (SEMDEXA™) efficacy and […] Read More »

April 25, 2022

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Expanding Its Direct Distribution Network to National And Regional Wholesalers And Pharmacies 

PALO ALTO, CA. April 25, 2022 /Newswire/ — Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced the expansion of its direct distribution network to national […] Read More »

April 25, 2022

Dr. Henry Ji, Sorrento Therapeutics’ Chairman And Ceo And Scilex Holding Company’s Executive Chairman, To Present At The B. Riley Securities’ 2022 Virtual Neuro & Opthalmology Healthcare Conference (April 27-28, 2022)

San Diego, CA and Palo Alto, CA., April 25, 2022 (GLOBE NEWSWIRE) – Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) today announced that Dr. Henry Ji, Chairman and CEO of Sorrento and Executive Chairman of Scilex Holding Company (“Scilex”), will participate in the B. Riley Virtual Neuro & Opthalmology Healthcare Conference at 10:00AM ET on April […] Read More »

April 12, 2022

Scilex Holding Company a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, Laura Hamill

PALO ALTO, CA. April 12, 2022 /Newswire/ — Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced the appointment of Laura Hamill, an accomplished pharmaceutical and […] Read More »

April 4, 2022

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announces continuous sales growth in ZTlido® with preliminary gross sales of approximately $8.1 million during the month of March 2022 and $18.4 million for 1Q2022

ZTlido 53% year-over-year preliminary unaudited gross sales in March 2022 Select payor accounts representing approximately 200 million of the over 300 million covered lives across the United States PALO ALTO, CA. April 4, 2022 /Newswire/ — Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), […] Read More »

March 25, 2022

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enters into a Non-Binding Term Sheet for a $5 Billion Committed Equity Financing Facility to be Effective in Connection with the Closing of the Merger with Vickers Vantage Corp. I

PALO ALTO, CA. March 25, 2022 /Newswire/ — Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced that it has entered into a non-binding term sheet with B. Riley Principal Capital, […] Read More »

March 18, 2022

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA™) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential for First to Market Opportunity

SP-102 (SEMDEXA™), with 401 patients enrolled in the C.L.E.A.R. trial (Corticosteroid Lumbosacral Epidural Analgesia in Radiculopathy) experienced a rapid onset of pain relief, measured by Numeric Pain Rating Scale of average daily pain in the affected leg, with highly statistically significant improvement against placebo over the first 4 weeks, following a single transforaminal injection, LS […] Read More »

March 17, 2022

Scilex Holding Company, a Majority-owned Subsidiary OF Sorrento Therapeutics, Inc., to Become Publicly Traded Through a Merger With Vickers Vantage Corp. I

• Combined company expected to have a pro forma equity value post-money of approximately $1.64 billion, subject to potential adjustment, and with up to $140 million in expected gross proceeds before expenses, assuming no redemptions from Vickers Vantage Corp. I’s existing public shareholders, which would provide the current stockholders of Scilex an estimated ownership of […] Read More »

December 13, 2021

Scilex Holding Company Releases Corporate Presentation

Certain data in this Presentation was obtained from various external sources, and neither Scilex nor its affiliates, advisers or representatives has verified such data with independent sources. Accordingly, neither Scilex nor any of its affiliates, advisers or representatives makes any representations as to the accuracy or completeness of that data or undertakes any obligation to […] Read More »

December 9, 2021

Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting the

December 9, 2021 at 9:00 AM EST Scilex Holding Company, a commercial-stage, non-opioid biopharmaceutical pain management company, announces highly significant positive top-line results from its Phase 3 SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R Program for its novel, non-opioid, corticosteroid formulation, injectable dexamethasone sodium phosphate viscous gel product for the treatment of lumbosacral radicular pain (sciatica).   SP-102 […] Read More »

December 6, 2021

Scilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (NASDAQ: VCKA) (“SPAC”) Enter into Letter of Intent for Proposed Business Combination

Scilex Holding Company (Scilex) a subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), and Vickers Vantage Corp I (Nasdaq: VCKA) announce signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Scilex of approximately $1.5 billion, subject to adjustment, with expected gross proceeds of up to $140 million. Proposed business combination would create a publicly traded […] Read More »

August 19, 2021

Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido® Managed Care Coverage for Additional 33 Million Lives

PALO ALTO, Calif., Aug. 19, 2021 (GLOBE NEWSWIRE) — Scilex Holding Company (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), announced that, effective September 1, 2021, ZTlido® (lidocaine topical system) 1.8% has been added to multiple formularies, including two national PBMs (Pharmacy Benefit Managers), a national health plan and two regional health plans – thereby expanding coverage by up to 33 […] Read More »

July 20, 2021

Scilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management

PALO ALTO, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a wholly-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), today announced complete enrollment of SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program, a corticosteroid injectable dexamethasone sodium phosphate gel for the treatment of lumbosacral radicular pain, or sciatica. SP-102 has received Fast Track status from the FDA. Read More »

April 9, 2021

Scilex Holding, A Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for Ztlido® Label Expansion

Palo Alto, California, April 9, 2021 — Scilex Holding (“Scilex”), an over 99% owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”), has received a supplemental new drug application (sNDA) approval from the FDA for ZTlido® to make efficacy labeling change with clinical data. ZTlido® is the only lidocaine topical system that has been studied under […] Read More »

March 1, 2021

Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndrome

SAN DIEGO, Calif., March 01, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”) and Scilex Holdings Company (“Scilex”), a majority owned subsidiary of Sorrento, have entered into an exclusive licensing term sheet with Aardvark Therapeutics (“Aardvark”) to acquire Aardvark’s proprietary formulation, Delayed Burst Release Low Dose Naltrexone (DBR-LDN), or ARD-301, for the treatment of […] Read More »

October 9, 2020

Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released

SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today released details about its upcoming COVID-19 Pipeline Update call and webcast on October 13th, 2020. Title: Sorrento Therapeutics COVID-19 Pipeline Update, R&D Discussion and Management Q&A Conference ID: 2066037 Date of call: 10/13/2020 Time of call: 16:30 Eastern Time Expected Duration: 60 minutes + questions (analysts and general public) […] Read More »

October 7, 2020

Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in 2020

PALO ALTO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), today announced continuous sales growth in ZTlido® from quarter to quarter in 2020. Scilex expects third quarter 2020 ZTlido® net sales to grow 26% to approximately $7.2MM, compared to $5.7MM in Q2-2020. The preliminary third quarter 2020 net sales information presented in […] Read More »

October 1, 2019

Scilex Announces New Medicaid Agreements with CA & FL

PALO ALTO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) — Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), is excited to announce that its subsidiary, Scilex Pharmaceuticals, Inc., (together, with Scilex Holding Company, “Scilex”) has entered into multiple Medicaid agreements to facilitate access to ZTlido® (lidocaine topical system) 1.8% for nearly 6 […] Read More »

September 30, 2019

Scilex Holding Company Strengthens Board of Directors with Appointment of Two Highly Accomplished Pharmaceutical and Biotechnology Executives, Scott Whitcup, M.D. and Elizabeth Czerepak

PALO ALTO, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) — Scilex Holding Company (Scilex) today announced that it appointed Scott M. Whitcup, M.D. as lead independent director to its Board of Directors in May of this year. Dr. Whitcup is founder and Chief Executive Officer of Akrivista, LLC and Whitecap Biosciences, LLC, two companies focused on […] Read More »

September 23, 2019

Scilex Holding Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) — Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), announced that it has confidentially submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission (the “SEC”) relating to its proposed initial public offering of its common stock. The […] Read More »

April 15, 2019

Scilex Semnur Corporate Presentation

DOWNLOAD PRESENTATION Read More »

March 27, 2019

Scilex Holding, a Subsidiary of Sorrento Therapeutics, Announces Phase 2 Trial Results for its Leading SP-102 Program

Complete Enrollment of Phase 2 Trial to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102 Administered by Epidural Injection in Subjects with Lumbosacral Radiculopathy, a.k.a. sciatica All subjects experienced rapid reduction of leg and back pain following two SP-102 injection treatments, with group median for average pain in affected leg reduced over 50% throughout […] Read More »

March 22, 2019

Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management

Semnur’s SP102, addressing multi-billion dollar unmet market needs, in Pivotal Phase 3 Trial with Fast Track Status from the FDA With non-opioid ZTlido, RTX, and SP102 commercial and near-commercial product lines, Sorrento and its subsidiaries are addressing $63 billion market in pain management (1) PDF Version SAN DIEGO, March 22, 2019 (GLOBE NEWSWIRE) — Sorrento […] Read More »

January 14, 2019

Scilex Announces Addition of ZTlido® to Express Scripts National Formularies

SAN DIEGO, Jan. 14, 2019 (GLOBE NEWSWIRE) — Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), today announced that Express Scripts has added ZTlido® (lidocaine topical system) 1.8% to its commercial national formularies representing nearly 30 million lives.  ZTLIDO is indicated for relief of pain associated with postherpetic neuralgia (PHN), also […] Read More »

January 14, 2019

Scilex Announces ZTlido® Insurance Coverage for ~100 Million Insured Lives(1)

SAN DIEGO, Jan. 14, 2019 (GLOBE NEWSWIRE) — Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), today announced that ZTlido® (lidocaine topical system) 1.8% (ZTLIDO) is covered by nearly 100M U.S. insured lives1.  ZTLIDO is indicated for relief of pain associated with postherpetic neuralgia (PHN), also referred to as post-shingles pain. […] Read More »

September 20, 2018

Scilex Announces Pricing and Availability of ZTlido™ for the Commercial Launch of its First Product in October of 2018

SAN DIEGO, September 19, 2018 – Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), today announced that the Wholesale Acquisition Cost (WAC) for ZTlido™ (lidocaine topical system) 1.8% (ZTLIDO) is $8.98 per patch and is now listed in pricing compendia. Scilex expects commercial availability of ZTlido through wholesale distribution in […] Read More »

September 7, 2018

Scilex Presents ZTlido™ Data on Superior Adhesion over Lidocaine Patch Formulation

Data Presented at PAINWeek® Also Showed ZTlido Was Well-Tolerated and Demonstrated Bioequivalence to Lidoderm® Patch1,2 Study Results Make Strong Case for ZTlido as Non-Opioid Treatment for Post-Shingles Pain SAN DIEGO, September 7, 2018 – Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), today announced data showing ZTlido™ (lidocaine topical system) […] Read More »

February 28, 2018

Sorrento Therapeutics Subsidiary, Scilex, Receives US FDA Approval for Non-Opioid ZTlido™ (lidocaine topical system) 1.8% for PHN Pain

SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”), and its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex”), received approval from the U.S. Food and Drug Administration (FDA) for ZTlido™ (lidocaine topical system) 1.8%. ZTlido is indicated for the relief of pain associated with post-herpetic neuralgia (PHN), also referred to as […] Read More »

November 14, 2017

SCILEX PHARMACEUTICALS, SORRENTO THERAPEUTICS’ SUBSIDIARY, FILES MARKETING AUTHORIZATION APPLICATION IN THE EUROPEAN UNION FOR ZTLIDO™

SAN DIEGO, November 14th, 2017 /GlobalNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”), announced today that Scilex Pharmaceuticals Inc. (“Scilex”), a majority-owned subsidiary of Sorrento, filed the European Marketing Authorization Application (MAA) for its lead product candidate, ZTlido™ (lidocaine medicated plaster 1.8%), through a hybrid regulatory pathway with the Medicines and Healthcare products Regulatory Agency […] Read More »

September 12, 2017

FDA Acknowledges Receipt Of Sorrento Therapeutics Inc, NDA For ZTlido™; PDUFA Date Set For February 28, 2018

SAN DIEGO, Sept. 12, 2017 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”), announced today that SCILEX Pharmaceuticals Inc. (“SCILEX”), a majority-owned subsidiary of Sorrento, has received from the U.S. Food and Drug Administration (“FDA”) acknowledgement of receipt of its recently resubmitted New Drug Application (“NDA”) for ZTlido™ (lidocaine patch 1.8%) which has been considered a […] Read More »

August 31, 2017

Sorrento Therapeutics’ Pain Subsidiary, SCILEX Pharmaceuticals, Announces Positive Data from Head to Head Adhesion Study with its Lead Product, ZTlido™

– ZTlido™ demonstrated superior adhesion as compared to the reference product in the EU SAN DIEGO, June 14, 2017 /PRNewswire/ — SCILEX Pharmaceuticals Inc. (“SCILEX”), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) today announced that its lead investigational product, ZTlido™ (lidocaine medicated plaster 1.8%), has demonstrated superior adhesion versus the EU reference product Versatis® […] Read More »

August 30, 2017

Sorrento Therapeutics, Inc. Submits NDA For ZTlido™ Next-Generation Lidocaine Patch

SAN DIEGO, Aug. 29, 2017 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”), announced today that SCILEX Pharmaceuticals Inc. (“SCILEX”), a majority-owned subsidiary of Sorrento, resubmitted the NDA and responded to all of FDA comments related to the initial NDA submission for its lead product candidate, ZTlido™ (lidocaine patch 1.8%).  ZTlido is a next-generation non-opioid, […] Read More »

January 9, 2017

Sorrento Subsidiary, SCILEX Pharmaceuticals, Announces Key Endpoints Met in the European Union Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido™

– Marketing Authorization Application is expected to be filed in mid-2017 NEWS PROVIDED BY Sorrento Therapeutics, Inc. Jan 09, 2017, 09:00 ET SAN DIEGO, Jan. 9, 2017 /PRNewswire/ — SCILEX Pharmaceuticals Inc. (“SCILEX”), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) today announced that its pivotal study for its lead investigational product, ZTlido™ (lidocaine patch […] Read More »

December 5, 2016

Sorrento Subsidiary, SCILEX Pharmaceuticals Announces Key Endpoints Met in Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido™

– 505(b)(2) NDA resubmission is expected in mid-2017 December 5, 2016 SAN DIEGO, Dec. 5, 2016 /PRNewswire/ — SCILEX Pharmaceuticals Inc. (“SCILEX”), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) today announced that its pivotal study for lead investigational product, ZTlido™ (lidocaine patch 1.8%), has met a primary endpoint establishing comparative pharmacokinetics and a secondary […] Read More »

November 8, 2016

Sorrento Therapeutics Closes Acquisition of Scilex

November 8, 2016 SAN DIEGO, Nov. 8, 2016 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; “Sorrento”) and Scilex Pharmaceuticals Inc. (“SCILEX”) announced today the closing of a transaction by which Sorrento acquired a majority of SCILEX.  Sorrento acquired approximately 72% of the outstanding common stock of SCILEX for a net purchase price of up to approximately […] Read More »

April 22, 2016

SCILEX Pharmaceuticals Reports First-Line Treatments Including Lidocaine Patches for Post-Herpetic Neuralgia Are Significantly Underutilized

MALVERN, Pa.–(BUSINESS WIRE)–SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, reported data on how healthcare providers are currently treating patients with post-herpetic neuralgia (PHN) and how their prescribing choices compare with recommended guidelines. The data were presented in two studies at the AMCP Managed […] Read More »

February 23, 2016

SCILEX Pharmaceuticals Announces Senior Industry Hires

Malvern, PA, February 23, 2016 – SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced the appointment of medical and regulatory affairs executives, as the Company advances in its assessment of several unique drug candidates. ZTlido™ (lidocaine patch 1.8%) is the Company’s first […] Read More »

December 10, 2015

SCILEX Pharmaceuticals Announces Executive Hires – Expanding team supports the ramp up of pain product suite

MALVERN, Pa., Dec. 10, 2015 /PRNewswire/ — SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced the appointment of senior executives as it builds its team to support the commercialization of ZTlido™. ZTlido™ (lidocaine patch 1.8%) is a next-generation patch being developed for […] Read More »

September 17, 2015

FDA Accepts SCILEX Pharmaceuticals’ NDA Filing for ZTlido™

Malvern, PA, September 16, 2015 – SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced that the FDA has accepted for filing its new drug application for ZTlido™ (lidocaine patch 1.8%). This marks a significant step on the path to commercialization for ZTlido™, […] Read More »

June 9, 2015

SCILEX Pharmaceuticals Announces Appointments of Internationally Recognized Industry Experts

Dr. Sanjay Gupta, President of the American Pain Association and a renowned physician with pain management expertise Dr. Philip Gerbino, an award-winning global pharmaceutical consultant and industry expert on market access MALVERN, Pa., June 8, 2015 /PRNewswire/ — SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment […] Read More »

April 6, 2015

SCILEX PHARMACEUTICALS ANNOUNCES STRATEGIC INVESTMENT BY ITOCHU CHEMICAL FRONTIER CORPORATION

SCILEX PHARMACEUTICALS ANNOUNCES STRATEGIC INVESMENT BY ITOCHU CHEMICAL FRONTIER CORPORATION Malvern, PA – March 19, 2015 – SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced that ITOCHU CHEMICAL FRONTIER Corporation (ICF, Tokyo Japan), a member of ITOCHU Corporation (ITOCHU, 8001: TYO, ITOCY: OTC), one […] Read More »

September 11, 2014

SCILEX TO PRESENT AT AEGIS CAPITAL HEALTHCARE & TECHNOLOGY CONFERENCE

SCILEX TO PRESENT AT AEGIS CAPITAL HEALTHCARE & TECHNOLOGY CONFERENCE   MALVERN, PA. September 10, 2014 /PRNewswire/ — SCILEX Pharmaceuticals Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced that it will participate in the upcoming Aegis Capital 2014 Healthcare & Technology Conference to be […] Read More »

August 11, 2014

SCILEX Pharmaceuticals Featured In Philadelphia Business Journal

Please click the link below to read the complete article. http://www.bizjournals.com/philadelphia/blog/health-care/2014/08/pain-drug-developer-reels-in-5.html Read More »

May 5, 2014

SCILEX Pharmaceuticals Appoints Accounting And Finance Veteran Jerrold Sendrow To Board Of Directors

Mr. Sendrow Joins Pharmaceuticals Product Development and Regulatory Expert Eric Floyd, Ph.D. on the Board Malvern, PA – SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced the appointment of finance and accounting veteran Jerrold Sendrow to the Company’s board of directors. Mr. Sendrow brings […] Read More »

March 24, 2014

SCILEX Pharmaceuticals Announces Filing of Investigational New Drug Application for Ztlido™

Pivotal pharmacokinetic bridging clinical study anticipated to begin in May. Malvern, PA – SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products for the treatment of pain, today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration for its first product Ztlido™ […] Read More »

March 21, 2014

SCILEX Pharmaceuticals Announces Completion of $5,000,000 Private Placement

Funds to be used for the clinical development of the Company’s first product Ztlido™ (lidocaine patch 1.8%) Malvern, PA – SCILEX Pharmaceuticals, Inc., today announced that the company has entered into definitive agreements for a private placement of common stock and warrants. The gross proceeds of the placement are expected to be approximately $5,000,000, before […] Read More »